Workflow
报喜鸟(002154) - 2023 Q3 - 季度财报
SAINT ANGELOSAINT ANGELO(SZ:002154)2023-10-25 16:00

Financial Performance - The company's net profit attributable to shareholders decreased by 65.44% to CNY 3,455,077.67 compared to CNY 9,997,852.18 in the same period last year [8]. - Net profit attributable to shareholders for Q3 2023 was ¥147,521,323.56, up 23.28% compared to the same period last year [15]. - The net profit after deducting non-recurring gains and losses was ¥139,904,702.98, reflecting a 24.90% increase year-over-year [15]. - Net profit for the period reached $577.90 million, compared to $394.20 million in the previous year, marking a growth of approximately 46.5% [29]. - The company reported operating profit of $712.02 million, compared to $501.03 million, representing an increase of approximately 42.1% [29]. Revenue and Costs - The company's revenue for Q3 2023 reached ¥1,196,794,484.82, representing a 14.80% increase year-over-year [15]. - Total operating revenue for the third quarter reached ¥3,667,434,448.06, an increase of 20.7% compared to ¥3,038,261,267.95 in the same period last year [36]. - Total operating costs amounted to ¥3,005,489,444.04, up 16.7% from ¥2,572,370,998.91 in the previous year [36]. Assets and Liabilities - As of September 30, 2023, the total current assets amounted to CNY 4,197,832,144.74, an increase of 14.48% from CNY 3,667,116,896.15 at the beginning of the year [5]. - The total assets at the end of Q3 2023 amounted to ¥6,658,264,529.61, an increase of 11.15% from the end of the previous year [15]. - The company's total liabilities rose to $2.34 billion, up from $1.94 billion, reflecting an increase of about 20.5% [28]. - The total liabilities increased to CNY 1,200,701,906.64, reflecting a growth of 1.15% from CNY 1,179,016,835.76 [5]. Cash Flow - The net cash flow from operating activities surged to CNY 431,655,691.65, a significant increase of 28,088.86% from CNY 1,531,299.07 [8]. - Cash flow from operating activities for the year-to-date period was ¥431,655,691.65, showing a significant increase of 28,088.86% [15]. - Cash and cash equivalents at the end of the period were ¥1,205,697,425.61, compared to ¥1,013,335,524.09 at the end of the previous year, indicating an increase of 19% [43]. - The cash and cash equivalents net decrease was CNY -181,027,477.31, an improvement of 79.34% compared to CNY -876,211,947.99 in the same period last year [8]. Investments and Expenses - Research and development expenses increased by 30.45% to CNY 72,029,417.13 from CNY 55,215,162.78 year-on-year [8]. - Research and development expenses increased to ¥72,029,417.13, compared to ¥55,215,162.78 in the previous year, reflecting a growth of 30.5% [36]. - Sales expenses increased to ¥1,355,035,219.57, up from ¥1,192,568,056.67, reflecting a rise of 13.7% [36]. - The company reported a 354.18% increase in investment income, reaching CNY 23,560,269.32 compared to CNY 5,187,484.20 in the previous year [8]. - The company reported a 168.34% increase in trading financial assets, totaling ¥521,993,000.00, attributed to increased investment in financial products [18]. Shareholder Equity - The total equity attributable to shareholders at the end of Q3 2023 was ¥4,198,482,212.66, up 6.70% from the previous year [15]. - The equity attributable to shareholders increased to $4.20 billion, compared to $3.93 billion, showing a growth of approximately 6.5% [28]. - Basic earnings per share for Q3 2023 was ¥0.1, an increase of 18.91% year-over-year [15]. - Basic earnings per share rose to ¥0.38, up from ¥0.26 in the same period last year, representing a growth of 46.2% [40]. Financing Activities - Cash flow from financing activities improved by 88.10%, resulting in a net cash flow of CNY -54,931,096.99 compared to CNY -461,630,154.24 in the previous year [8]. - The company’s total cash inflow from financing activities was ¥810,509,313.48, compared to ¥414,450,000.00 in the previous year, indicating a significant increase [43]. - The company reported a decrease in contract liabilities to $280.23 million from $323.90 million, a reduction of approximately 13.5% [27].